Go Pro
→ The 2026 beginners Guide to Gold IRAs (From Goldco Direct, LLC) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$438.46
-1.3%		$395.82
$269.77
▼
$447.03
$237.02B0.432.68 million shs101,760 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$64.14
+0.4%		$58.82
$34.08
▼
$64.14
$36.90B0.443.43 million shs239,614 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$552.41
-1.0%		$508.40
$374.17
▼
$560.25
$140.21B0.321.41 million shs47,079 shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$32.93
+0.0%		$30.47
$13.50
▼
$44.60
$2.15B-1.04828,594 shs43,138 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+0.29%+1.63%+13.69%+27.04%+56.46%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
+1.22%+3.17%+11.13%+14.34%+74.25%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+0.22%+1.90%+16.56%+24.87%+40.68%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-0.63%+0.92%+4.77%+88.44%+92.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$438.46
-1.3%		$395.82
$269.77
▼
$447.03
$237.02B0.432.68 million shs101,760 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$64.14
+0.4%		$58.82
$34.08
▼
$64.14
$36.90B0.443.43 million shs239,614 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$552.41
-1.0%		$508.40
$374.17
▼
$560.25
$140.21B0.321.41 million shs47,079 shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$32.93
+0.0%		$30.47
$13.50
▼
$44.60
$2.15B-1.04828,594 shs43,138 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+0.29%+1.63%+13.69%+27.04%+56.46%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
+1.22%+3.17%+11.13%+14.34%+74.25%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+0.22%+1.90%+16.56%+24.87%+40.68%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-0.63%+0.92%+4.77%+88.44%+92.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.43
Hold$381.68-12.95% Downside
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
3.00
Buy$60.86-5.12% Downside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.96
Moderate Buy$569.523.10% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$45.7138.82% Upside

Current Analyst Ratings Breakdown

Latest AMGN, ZBIO, VRTX, and RPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPositive$435.00
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$665.00
9/1/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$653.00
8/25/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/20/2026
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$427.00 ➝ $457.00
8/19/2026
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$362.00
8/19/2026
Amgen Inc. stock logo
AMGN
Amgen
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$375.00 ➝ $460.00
8/18/2026
Amgen Inc. stock logo
AMGN
Amgen
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$350.00 ➝ $400.00
8/18/2026
Amgen Inc. stock logo
AMGN
Amgen
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$303.00 ➝ $352.00
8/14/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$22.00 ➝ $32.00
8/14/2026
Amgen Inc. stock logo
AMGN
Amgen
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$360.00 ➝ $380.00
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$38.10B6.22$33.47 per share13.10$21.62 per share20.28
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$2.38B15.51$4.86 per share13.21$17.02 per share3.77
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B11.68$17.44 per share31.68$79.78 per share6.92
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$10M214.64N/AN/A$3.79 per share8.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0927.2517.983.1922.95%124.14%13.18%11/3/2026 (Estimated)
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$770.95M$1.4544.2611.601.4732.14%30.01%14.91%11/4/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1832.1629.832.4235.00%23.09%16.72%11/2/2026 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$8.99N/AN/AN/AN/A-122.45%-58.04%11/12/2026 (Estimated)

Latest AMGN, ZBIO, VRTX, and RPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.12-$1.77-$0.65-$1.77$15.00 million$1.00 million
8/5/2026Q2 2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$1.27$1.32+$0.05$0.04$758.93 million$674.14 million
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.30%+8.27%62.65%14 Years
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.941.47%+24.01%64.83%5 Years
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A

Latest AMGN, ZBIO, VRTX, and RPRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.29%8/21/20268/21/20269/11/2026
7/17/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
quarterly$0.23501.6%8/14/20268/14/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.88
2.80
2.80
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.57
9.93
9.93

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
54.35%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
18.84%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
22.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
80575.00 million466.67 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A65.18 million50.84 millionN/A

Recent News About These Companies

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356496/0/en/zenas-biopharma-to-present-at-upcoming-healthcare-investor-conferences.html
BlackRock Inc. Acquires New Shares in Zenas BioPharma, Inc. $ZBIO
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-acquires-new-shares-in-zenas-biopharma-inc-zbio-2026-08-31/
J. Goldman & Co LP Acquires New Position in Zenas BioPharma, Inc. $ZBIO
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-j-goldman-co-lp-acquires-new-position-in-zenas-biopharma-inc-zbio-2026-08-26/
Bank of America Corp DE Purchases 341,187 Shares of Zenas BioPharma, Inc. $ZBIO
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-purchases-341187-shares-of-zenas-biopharma-inc-zbio-2026-08-26/
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Brokerages
August 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-inc-nasdaqzbio-given-average-recommendation-of-moderate-buy-by-brokerages-2026-08-23/
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/18/3347237/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
HC Wainwright Predicts Higher Earnings for Zenas BioPharma
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-predicts-higher-earnings-for-zenas-biopharma-2026-08-18/
Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-walleye-capital-llc-takes-531-million-position-in-zenas-biopharma-inc-zbio-2026-08-15/
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharmas-zbio-buy-rating-reaffirmed-at-guggenheim-2026-08-14/
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharmas-zbio-outperform-rating-reiterated-at-wedbush-2026-08-14/
Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-nasdaqzbio-issues-earnings-results-2026-08-13/
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zenas-biopharma-nasdaqzbio-stock-price-down-66-on-disappointing-earnings-2026-08-13/
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344367/0/en/zenas-biopharma-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees
July 17, 2026  |  quiverquant.comQ
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/17/3329284/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise
July 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4921888-zenas-biopharma-obexelimab-could-build-an-autoimmune-franchise
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
July 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zenas-biopharma-zbio-best-ipo-135853785.html
Zenas BioPharma Inc ZBIO
June 27, 2026  |  morningstar.comM
Zenas BioPharma Announces Positive Phase 3 Obexelimab Results
June 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZBIO/pressreleases/36903055/zenas-biopharma-announces-positive-phase-3-obexelimab-results/
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
June 21, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/21/zenas-biopharma-s-ceo-purchased-60-000-company-shares-here-s-a-deeper-look-at-the-transaction/
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313812/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amgen stock logo

Amgen NASDAQ:AMGN

$438.46 -5.66 (-1.27%)
As of 10:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$64.14 +0.26 (+0.41%)
As of 10:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$552.40 -5.56 (-1.00%)
As of 10:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$32.93 +0.01 (+0.03%)
As of 10:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas